A Phase 3 interventional study of JNT-517 and JNT-517 Matching Placebo in Phenylketonuria, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 26 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
…and 19 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.
Among the 93 studies in Phenylketonurias with a site in United States, this one is the 11th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 13 of the 20 other live ones, and was the 87th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:
Aptatek BioSciences, Inc · Sites in United States
Ages 1+
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65 · Healthy volunteers
Maze Therapeutics · Sites in United States, France, United Kingdom
Ages 18–75
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
Agios Pharmaceuticals, Inc. · Sites in United States, Poland
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 21 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 33 across the 63 interventional studies, 28 across the 29 observational. Of the 70 that completed or were terminated, 28 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 6 studies filed under Phenylketonurias — fewer than ten, so there is no comparison to draw.
6 of the studies in Phenylketonurias with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06628128Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Long-Term Study of JNT-517 in Participants With Phenylketonuria | 2027-11-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT07713758Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function | 2027-02-09 |
| NCT07220265University of Missouri-ColumbiaImpact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers | 2027-03-01 |
| NCT07551921Aptatek BioSciences, IncPheCheck™ Validation Study | 2027-03-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 93 studies in Phenylketonurias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria.
Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be excluded from the study if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive JNT-517 orally, twice daily (BID), with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.
Drug: JNT-517
Participants will receive JNT-517 orally, BID, with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally for 46 weeks in Period 2.
Drug: JNT-517
Participants will receive JNT-517 matching placebo orally, BID for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.
Drug: JNT-517 Matching Placebo
JNT-517 orally
JNT-517 matching placebo orally
Absolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Dose Group at End of Period 1
Time frame: Baseline to End of Period 1 (Week 6)
Percent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Group at End of Period 1
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe Less Than (<) 600 Micromoles per Liter (µmol/L) at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the High Dose BID Group
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the High Dose BID Group
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe <600 µmol/L at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the Low Dose BID Group
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the Low Dose BID Group
Time frame: Baseline to End of Period 1 (Week 6)
Absolute Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 Low Dose BID Group at End of Period 1
Time frame: Baseline to End of Period 1 (Week 6)
Percent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 Low Dose BID Group at End of Period 1
Time frame: Baseline to End of Period 1 (Week 6)
Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants With Baseline Inattentive Subscore More Than (>) 9 in the JNT-517 High Dose BID Group at End of Period 1
The ADHD-RS-5 Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.
Time frame: Baseline to End of Period 1 (Week 6)
Change From Baseline in Dietary Phe Intake While Achieving Plasma Phe <360 µmol/L at the End of Period 2 in Participants Receiving High Dose BID Group and Participating in the Diet Normalization
Time frame: Baseline to end of Period 2 (Week 52)
Number of Participants With Treatment-Emergent Adverse Events and Serious Treatment-Emergent Adverse Events in Periods 1 and 2
Time frame: From first dose of the study drug through Week 56
Percentage of Participants With More Than or Equal to (≥) 30 Percent (%) and ≥50% Reduction From Baseline in Plasma Phe at Week 6
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe Less Than (<) 120 µmol/L at End of Period 1 in the High Dose BID and Low Dose BID Groups
Time frame: End of Period 1 (Week 6)
Absolute Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 High Dose BID and Low Dose BID Groups
Time frame: Baseline to End of Period 1 (Week 6)
Percent Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 High Dose BID and Low Dose BID Groups
Time frame: Baseline to End of Period 1 (Week 6)
Percentage of Participants Achieving Plasma Phe <600 µmol/L Among Participants With Baseline ≥600 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2
Time frame: Baseline to End of Period 2 (Week 52)
Percentage of Participants Achieving Plasma Phe <360 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2
Time frame: End of Period 2 (Week 52)
Percentage of Participants Achieving Plasma Phe <120 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2
Time frame: End of Period 2 (Week 52)
Absolute Change From Baseline in Plasma Phe in the JNT-517 Low Dose BID and High Dose BID Dose Groups During Period 2
Time frame: Baseline to End of Period 2 (Week 52)
Percent Change From Baseline in Plasma Phe in the JNT-517 Low Dose BID and High Dose BID Dose Groups During Period 2
Time frame: Baseline to End of Period 2 (Week 52)
Percentage of Participants With ≥30% and ≥50% Reduction From Baseline in Plasma Phe During Period 2
Time frame: Baseline to End of Period 2 (Week 52)
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Stop Signal Reaction Time at End of Period 1
The CANTAB Stop Signal Task measures response inhibition. Stop Signal Reaction Time (SSRT) reflects the time required to inhibit a response, with longer times indicating poorer inhibitory control. A decrease from baseline indicates improvement.
Time frame: Baseline to End of Period 1 (Week 6)
Change From Baseline in ADHD-RS-5 Inattentive Subscore in Participants With Baseline Inattentive Subscore > 9 in the JNT-517 Low Dose BID Group at End of Period 1
The ADHD-RS-5 Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.
Time frame: Baseline to End of Period 1 (Week 6)
Change From Baseline in CANTAB Stop Signal Reaction Time During Period 2
The CANTAB Stop Signal Task measures response inhibition. SSRT reflects the time required to inhibit a response, with longer times indicating poorer inhibitory control. A decrease from baseline indicates improvement.
Time frame: Baseline to End of Period 2 (Week 52)
Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9 in the JNT-517 High Dose BID and Low Dose BID Dose Groups During Period 2
The ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.
Time frame: Baseline to End of Period 2 (Week 52)
Change From Baseline in Adult Self-rating Scale (ASRS) for Attention Deficit Hyperactivity Disorder in Participants Aged ≥12 years at Screening in Both JNT 517 Dose Groups During Periods 1 and 2
The ASRS has 18 questions covering two dimensions: attention deficits and hyperactive/impulsive behavior. Responses are rated on frequency using options like 'never,' 'rarely,' 'sometimes,' 'often,' or 'very frequently.' Each item scores from 0 (no problem) to 4 (most severe). The total ASRS score is the sum of all item scores ranging from 0 to 72, and higher scores indicate a high likelihood of ADHD.
Time frame: From first dose of the study drug through Week 56
Change From Baseline in Dietary Protein Intake While Maintaining Plasma Phe <360 µmol/L
Time frame: Baseline to End of Period 2 (Week 52)
Percentage of Participants Achieving Recommended Dietary Allowance (RDA) for Natural Intact Protein Intake While Maintaining Plasma Phenylalanine <360 µmol/L
Time frame: End of Period 2 (Week 52)
Percentage of Participants Achieving Two Times the RDA for Natural Intact Protein Intake Consistent With an Unrestricted Diet While Maintaining Plasma Phenylalanine <360 µmol/L
Time frame: End of Period 2 (Week 52)
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
…and 19 more changes, on the record history on ClinicalTrials.gov ↗
…and 19 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Repinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc. →